Group Purchasing Agreement Optimizes Invuity’s Sales Force to Support Rapid Multi-Specialty Adoption of EigrTM Illumination Technology   more >>

The NASDAQ OMX Group, Inc. announces an IPO of Chimerix (CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need.   more >>

Chimerix, Inc. announced the execution of a license agreement granting Merck exclusive worldwide rights to CMX157, novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection.   more >>

Chimerix, Inc. presented that its lead antiviral compound, CMX001, has the potential to reduce end-organ damage associated with BK virus (BKV) in hematopoietic stem cell transplant (HSCT) recipients   more >>

Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. announced they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines.   more >>

Invuity, a leading developer of state-of-the-art surgical visualization and illumination technology, has raised a $25 million Series D round of financing   more >>

Coherus BioSciences, Inc. and Daiichi Sankyo, Co. Ltd. announced the execution of an exclusive agreement to develop and commercialize biosimilar forms of etanercept and rituximab in certain Asian countries including Japan   more >>

Invuity, a leading developer of state-of-the-art illuminated surgical technology, today introduced its illuminated breast retractor system at the American College of Surgeons' 97th Annual Clinical Congress in San Francisco   more >>

iScience Interventional pioneers of site-specific therapies for anterior and posterior ocular diseases, today announced it has signed a clinical and commercial supply agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) and its affiliates.   more >>

Chimerix, Inc. has been awarded a contract that will finance the smallpox drug development with committed funding of $24.8 million during the first year and subsequent option to bring the total contract value to $81.1 million.   more >>

Sonoma Orthopedic Products announced that it has completed the acquisition of certain key assets of NovaLign Orthopaedics, Inc.   more >>

Article about the business potential of just announced licensing deal between Proteus Biomedical and Novartis.   more >>

WSJ reporter Brian Gormley interviews Dr. Graham Crooke on the BiPar investment model.   more >>